L4 STRUCTURE UPLOADED

=> d
L4 HAS NO ANSWERS
L4 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l4 full
FULL SEARCH INITIATED 11:29:20 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1649 TO ITERATE

100.0% PROCESSED 1649 ITERATIONS 160 ANSWERS
SEARCH TIME: 00.00.01

L5 160 SEA SSS FUL L4

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.33	358.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-3.65

FILE 'CAPLUS' ENTERED AT 11:29:23 ON 10 JAN 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 10 Jan 2005 VOL 142 ISS 3
FILE LAST UPDATED: 9 Jan 2005 (20050109/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l5
L6          53 L5
```

L7 STRUCTURE UPLOADED

=> d
L7 HAS NO ANSWERS
L7 STR



G1 Cb,Cy,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l7 full
FULL SEARCH INITIATED 11:31:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1804 TO ITERATE

100.0% PROCESSED 1804 ITERATIONS 119 ANSWERS
SEARCH TIME: 00.00.01

L8 119 SEA SSS FUL L7

```
=> s l9 and pd<1995
      15883355 PD<1995
                  (PD<19950000)
L11           5 L9 AND PD<1995

=> d l11 1-5 ibib abs hitstr
```

L11 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1991:123091 CAPLUS
DOCUMENT NUMBER: 114:123091
TITLE: Preparation of boropeptide protease inhibitors as neoplasm inhibitors and virucides
INVENTOR(S): Kinder, David H.; Ames, Matthew M.
PATENT ASSIGNEE(S): Mayo Foundation for Medical Education and Research, USA
SOURCE: U.S., 11 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4963655	A	19901016	US 1988-199891	19880527 <--
US 5106948	A	19920421	US 1990-574294	19900828 <--
US 5159060	A	19921027	US 1992-823674	19920121 <--

PRIORITY APPLN. INFO.: US 1988-199891 A2 19880527
US 1990-574294 A3 19900828

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds., e.g., I, II, and III, were prepared as neoplasm inhibitors and virucides. Thus, alanylborovaline derivative I, prepared via the corresponding pinanediol aminoboronic ester IV, at 1.47 μM gave 93% inhibition of growth of human melanoma A375 cells after 96 h.

IT **132472-62-9P 132472-67-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as virucide and neoplasm inhibitor)

RN 132472-62-9 CAPLUS
CN Boronic acid, [1-[[2-[[(7-methoxy-2-oxo-2H-1-benzopyran-4-yl)acetyl]amino]-1-oxopropyl]amino]-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 132472-67-4 CAPLUS
CN Boronic acid, [1-[[2-[[(7-methoxy-2-oxo-2H-1-benzopyran-4-yl)acetyl]amino]-1-oxopropyl]amino]-2-phenylethyl]- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:532823 CAPLUS
DOCUMENT NUMBER: 113:132823
TITLE: Peptides containing α-aminoboronate groups for treatment of human immunodeficiency virus-caused disease
INVENTOR(S): Moelling, Karin; Paessens, Arnold; Kleemann, Heinz Werner; Urbach, Hansjoerg; Koenig, Wolfgang; Ruppert, Dieter; Winkler, Irwin
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3827340	A1	19900215	DE 1988-3827340	19880812 <--
EP 354522	A1	19900214	EP 1989-114601	19890808 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8903957	A	19900213	DK 1989-3957	19890811 <--
NO 8903240	A	19900327	NO 1989-3240	19890811 <--
AU 8939513	A1	19900329	AU 1989-39513	19890811 <--
JP 02091023	A2	19900330	JP 1989-207061	19890811 <--
ZA 8906150	A	19910130	ZA 1989-6150	19890811 <--

PRIORITY APPLN. INFO.: DE 1988-3827340 A 19880812
OTHER SOURCE(S): MARPAT 113:132823
GI For diagram(s), see printed CA Issue.
AB A1A2NHCHR2B(XR3)YR4 [I; A1 = R1R6NCHR5CO, R1R7CHCHR5CO, etc.; A2 = null, NR6CHR5CO; X, Y = O, NR8; R1,R2,R5 = H, (substituted) (unsatd.) alkyl, mono-, bi-, or tricycloalkyl, arylalkyl, mono- or bicyclic heterocyclyl, etc.; R3,R4 = H, (unsatd.)(substituted) alkyl; or B(XR3)YR4 = mono-, bi-, or tricyclic (unsatd.)(alkylated) 5-18 membered ring system; R6,R7 = H, alkyl; R5R6, R1R7 = atoms to complete a mono- or bicyclic (unsatd.) 5-12 membered ring; R8 = H, (substituted) (unsatd.) alkyl], were prepared as virucides for treatment of human immunodeficiency virus-induced disease. Thus, isovalerylphenylalanylnorvaline (H-Iva-Phe-Nva-OH) in THF at -20° was treated with N-methylmorpholine and Me2CHCH2O2CCl and then Et3N in THF. The mixture was then added to a -20° solution of 2-[(1'-amino-2'-cyclohexyl)ethyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane trifluoroacetate (preparation given) in THF. The mixture was stirred 22 h at room temperature to give H-Iva-Phe-NVa-Q. I inhibited HIV protease at 10-2-10-6 M.
IT **123706-09-2DP**, pinacol ester derivative **123706-09-2P**
123706-11-6P 123706-12-7P 123706-14-9P
123706-21-8P 123706-22-9P 123706-23-0P
123706-26-3P 123706-27-4P 123706-28-5P
123706-29-6P 123706-30-9P 123706-31-0P
123728-29-0P
RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of, as virucide for treatment of HIV-induced disease)

RN 123706-09-2 CAPLUS

CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-09-2 CAPLUS

CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-11-6 CAPLUS

CN L-Alaninamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-12-7 CAPLUS

CN L-Histidinamide, N-(3-methyl-1-oxobutyl)-3-(2-thienyl)-L-alanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-14-9 CAPLUS
CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cycloheptylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-21-8 CAPLUS
CN L-Histidinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cycloheptylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-22-9 CAPLUS
CN L-Histidinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclooctylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-23-0 CAPLUS
CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cycloundecylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:512988 CAPLUS
DOCUMENT NUMBER: 113:112988
TITLE: Thrombin and its inhibitors regulate morphological and biochemical differentiation of astrocytes in vitro
AUTHOR(S): Nelson, Robert B.; Siman, Robert
CORPORATE SOURCE: Neurobiol. Dep., Harvard Med. Sch., Boston, MA, 02115, USA
SOURCE: Developmental Brain Research (**1990**), 54(1), 93-104
CODEN: DBRRDB; ISSN: 0165-3806
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Flat, amorphous astroblasts in culture differentiate into rounded process-bearing cells after removal of serum from the media or following addition of dibutyryl cAMP (dbcAMP). In the present expts., addition of thrombin (10 nM) to rat primary astroglial cultures reversed both the spontaneous morphol. differentiation of astroblasts caused by serum removal, and the more extensive morphol. differentiation caused by pretreatment with dbcAMP. The astroblasts retained the ability to differentiate upon removal of thrombin from the medium. Proteolytic activity of thrombin was required for the reversal of differentiation. Moreover, addition of serine protease inhibitors active against thrombin elicited a prolonged morphol. differentiation rivaling that induced by dbcAMP, suggesting that inactivation of cell-associated thrombin might be sufficient for morphol. differentiation to occur. Two other serine proteases with a cleavage specificity similar to that for thrombin were ineffective in reversing differentiation. Both the induction of morphol. differentiation by dbcAMP and its reversal by thrombin were rapid, being essentially complete by 1 h. With more prolonged treatments, thrombin also reduced the dbcAMP-mediated increase in glutamine synthetase, a biochem. marker for astroglial differentiation. Thrombin also inhibited morphol. differentiation in C6 glioma and altered the morphol. of microglial cells; however, thrombin did not prevent neurite outgrowth in primary central neuronal cultures, in contrast to its previously reported effects on the neuroblastoma 2a cell line. Evidently, a proteolytic mechanism mediated by thrombin and its inhibitors and its inhibitors may underlie the regulation of astroglial differentiation.

IT **124216-01-9**
RL: BIOL (Biological study)
(astrocyte differentiation response to, thrombin inhibition in relation to)

RN 124216-01-9 CAPLUS
CN L-Phenylalaninamide, 1-benzoyl-L-prolyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



HCl

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1990:91790 CAPLUS
DOCUMENT NUMBER: 112:91790
TITLE: Peptide boronic acid inhibitors of trypsinlike proteases, their preparation and use as anticoagulants and inflammation inhibitors
INVENTOR(S): Kettner, Charles Adrian; Shenvi, Ashokkumar Bhikkappa
PATENT ASSIGNEE(S): du Pont de Nemours, E. I., and Co., USA
SOURCE: Eur. Pat. Appl., 61 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 293881	A2	19881207	EP 1988-108817	19880601 <--
EP 293881	A3	19900530		
EP 293881	B1	19930310		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5187157	A	19930216	US 1988-178368	19880406 <--
CA 1328332	A1	19940405	CA 1988-568224	19880531 <--
AT 86628	E	19930315	AT 1988-108817	19880601 <--
ES 2046237	T3	19940201	ES 1988-108817	19880601 <--
DK 8803044	A	19881206	DK 1988-3044	19880603 <--
FI 8802638	A	19881206	FI 1988-2638	19880603 <--
FI 97297	B	19960815		
FI 97297	C	19961125		
NO 8802472	A	19881206	NO 1988-2472	19880603 <--
AU 8817332	A1	19881208	AU 1988-17332	19880603 <--
AU 623592	B2	19920521		
JP 01063583	A2	19890309	JP 1988-135770	19880603 <--
JP 07030090	B4	19950405		
HU 49629	A2	19891030	HU 1988-2899	19880603 <--
HU 205141	B	19920330		
ZA 8803953	A	19900228	ZA 1988-3953	19880603 <--
IL 86613	A1	19930404	IL 1988-86613	19880603 <--
SU 1807988	A3	19930407	SU 1988-4356026	19880603 <--
CA 1333208	A1	19941122	CA 1991-616134	19910816 <--
CA 1339897	A1	19980602	CA 1991-616135	19910816
RU 2017749	C1	19940815	RU 1991-5010164	19911128 <--
US 5242904	A	19930907	US 1992-848296	19920309 <--
US 5250720	A	19931005	US 1992-852023	19920309 <--

PRIORITY APPLN. INFO.:	US 1987-59670	A	19870605
	US 1988-178368	A	19880406
	CA 1988-568224	A3	19880531
	EP 1988-108817	A	19880601

OTHER SOURCE(S): MARPAT 112:91790

AB Peptides containing C-terminal boronic acid derivs. of lysine, ornithine, arginine, or homoarginine and corresponding isothiuronium analogs are reversible inhibitors of trypsinlike serine proteases such as thrombin, plasma kallikrein, and plasmin and are useful in treatment of blood coagulation disorders and inflammation. The peptides have the structure R1(A3qA2pA1o)nNHCHR2BY1Y2 (Y1, Y2 = OH, F; or Y1Y2 = dihydroxy compound moiety; R1 = peptide of 1-20 residues, C1-20 acyl or sulfonyl, H, N-terminal protecting group; A1-A3 = L- or D-amino acid; R2 = substituted alkyl; n, o, p, q = 0, 1) (I). In rats given Ac-D-Phe-boro-Arg (II) (where boro-Arg has a boronic acid moiety in place of CO2H) orally at 1 mg, the blood clotting time (thrombin time) was increased to >300 s for 3 h (control, 34 s). II-HCl at 5 nm inhibited the activity of human

thrombin (1.0 nM) by 97% in vitro (initial substrate concentration 0.10 mM). Allyl bromide was hydroborated with catechol borane, transesterified with (+)-α-pinanediol, homologated, and aminated to yield 1-amino-4-bromobutyl boronate pinanediol.HCl, which was coupled to Boc-D-Phe-Pro (Boc = tert-butoxycarbonyl) (preparation given) and converted in 5 addnl. steps to II-HCl.

IT **124216-01-9P 124216-02-0P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as protease inhibitor)

RN 124216-01-9 CAPLUS
CN L-Phenylalaninamide, 1-benzoyl-L-prolyl-N-[4-[(aminoiminomethyl)amino]-1-boronobutyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 124216-02-0 CAPLUS
CN L-Phenylalaninamide, 1-benzoyl-L-prolyl-N-[4-[(aminoiminomethyl)amino]-1-(difluoroboryl)butyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT **124216-61-1**
RL: BIOL (Biological study)
(protease inhibition by)

RN 124216-61-1 CAPLUS
CN L-Phenylalaninamide, 1-benzoyl-L-prolyl-N-[4-[(aminoiminomethyl)amino]-1-(difluoroboryl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 1989:633679 CAPLUS
DOCUMENT NUMBER: 111:233679
TITLE: Preparation and testing of borylpeptides as renin inhibitors
INVENTOR(S): Kleemann, Heinz Werner; Urbach, Hans Joerg; Ruppert, Dieter; Schoelkens, Bernward
PATENT ASSIGNEE(S): Hoechst A.-G., Fed. Rep. Ger.
SOURCE: Eur. Pat. Appl., 28 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 315574	A2	19890510	EP 1988-710042	19881029 <--
EP 315574	A3	19900822		
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3836911	A1	19890524	DE 1988-3836911	19881029 <--
FI 8805068	A	19890506	FI 1988-5068	19881103 <--
ZA 8808239	A	19890726	ZA 1988-8239	19881103 <--
US 5169841	A	19921208	US 1988-266960	19881103 <--
DK 8806172	A	19890506	DK 1988-6172	19881104 <--
NO 8804925	A	19890508	NO 1988-4925	19881104 <--
AU 8824693	A1	19890511	AU 1988-24693	19881104 <--
AU 608379	B2	19910328		
JP 01163185	A2	19890627	JP 1988-277568	19881104 <--

PRIORITY APPLN. INFO.: DE 1987-3737498 A 19871105
DE 1988-3818436 A 19880531
OTHER SOURCE(S): CASREACT 111:233679; MARPAT 111:233679
GI For diagram(s), see printed CA Issue.
AB A1A2NHCHR2B(XR3)YR4 [I; A1 = R1R6NCHR5CO, R1R12CHCHR5CO, R1R6NCHR5CHR7CHR8CHR9CO, etc.; A2 = null, NR6CHR5CO; X, Y = O, NR13; R1, R2, R5, R9 = H, (substituted) (unsatd.) C1-12 alkyl, C3-18 cycloalkyl, C6-14 aryl, cycloalkylalkyl, aralkyl, all of which may be coupled to CO, OCO, SO2, SO, HNSO2, HNCO, CHOH, or NOH; R3, R4 = H, (substituted) C1-12 alkyl; R3R4 = atoms to complete a mono-, bi-, or tricyclic (unsatd.) (substituted) ring system; R6 = H, C1-8 alkyl; R5R6 = atoms to complete a mono- or bicyclic (unsatd.) ring; R7, R8 = H, OH, amino, F, aminoalkyl, hydroxyalkyl, (unsatd.) C1-4 alkyl; R12 = H, C1-8 alkyl; R1R12 = atoms to complete a mono- or bicyclic (unsatd.) C5-12 ring; R13 = H, (unsatd.) (substituted) C1-12 alkyl], useful as renin inhibitors, were prepared Aminodioxaborolane II.CF3CO2H (Q = H) (prepared from (MeO)3B and (cyclohexylmethyl)magnesium bromide) in THF at -20° was treated with a mixture of IVA-Phe-Nva (IVA = isovaleryl, Nva = norvalyl), Me2CHCH2OCOCl, 4-methylmorpholine, and Et3N in THF and the mixt was stirred 1 h at -20° and 2 h at room temperature to give II (Q = NVA-Phe-Nva). The latter inhibited human plasma renin with an IC50 of 4.2 + 10-7 M.

IT **123706-09-2DP**, pinanyl ester derivative **123706-09-2P**
123706-11-6P 123706-12-7P 123706-14-9P
123706-20-7P 123706-21-8P 123706-22-9P
123706-23-0P 123706-26-3P 123706-27-4P
123706-28-5P 123706-29-6P 123706-30-9P
123706-31-0P 123728-29-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of, as renin inhibitor)

RN 123706-09-2 CAPLUS
CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-09-2 CAPLUS
CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-11-6 CAPLUS
CN L-Alaninamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cyclohexylethyl)-3-(2-thienyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-12-7 CAPLUS
CN L-Histidinamide, N-(3-methyl-1-oxobutyl)-3-(2-thienyl)-L-alanyl-N-(1-borono-2-cyclohexylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123706-14-9 CAPLUS
CN L-Norvalinamide, N-(3-methyl-1-oxobutyl)-L-phenylalanyl-N-(1-borono-2-cycloheptylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



```
=> E ADAMS JULIAN/AU 25
E1            1     ADAMS JULAIN/AU
E2            4     ADAMS JULIA A/AU
E3          181 --> ADAMS JULIAN/AU
E4            5     ADAMS JULIAN J/AU
E5            1     ADAMS JULIAN R J/AU
E6            3     ADAMS JULIE/AU
E7            4     ADAMS JULIE A/AU
E8            1     ADAMS JULIE M/AU
E9            7     ADAMS JULIUS R/AU
E10           1     ADAMS JULIUS T/AU
E11           2     ADAMS JULYE M/AU
E12           8     ADAMS JUNIUS G/AU
E13          21     ADAMS JUNIUS G III/AU
E14           1     ADAMS JUNIUS GREENE III/AU
E15           1     ADAMS JUNIUS III/AU
E16           1     ADAMS JURGEN/AU
E17          26     ADAMS K/AU
E18           5     ADAMS K A/AU
E19           7     ADAMS K A H/AU
E20           3     ADAMS K B/AU
E21           5     ADAMS K E/AU
E22           1     ADAMS K F/AU
E23           1     ADAMS K F JR/AU
E24           5     ADAMS K G/AU
E25          27     ADAMS K H/AU

=> S (E3) AND (PROTEAS?)
            181 "ADAMS JULIAN"/AU
         107110 PROTEAS?
L5           80 ("ADAMS JULIAN"/AU) AND (PROTEAS?)

=> S (E3) AND (PROTEASOME INHIB?)
            181 "ADAMS JULIAN"/AU
           8247 PROTEASOME
           1318 PROTEASOMES
           8429 PROTEASOME
                  (PROTEASOME OR PROTEASOMES)
        1712056 INHIB?
           2131 PROTEASOME INHIB?
                  (PROTEASOME(W)INHIB?)
L6           77 ("ADAMS JULIAN"/AU) AND (PROTEASOME INHIB?)

=> s l6 and boronic ester?
           5011 BORONIC
         864005 ESTER?
            386 BORONIC ESTER?
                  (BORONIC(W)ESTER?)
L7            2 L6 AND BORONIC ESTER?

=> d l7 1-2

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2005 ACS on STN
AN   2000:452347  CAPLUS
DN   133:89798
TI   Preparation of peptidyl boronic ester and acid
     compounds as proteasome inhibitors
IN   Adams, Julian; Ma, Yu-Ting; Stein, Ross; Baevsky, Matthew;
     Grenier, Louis; Plamondon, Louis
PA   Leukosite, Inc., USA
SO   U.S., 38 pp., Cont.-in-part of U.S. Ser. No. 330,525, abandoned.
     CODEN: USXXAM
DT   Patent
```

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6083903	A	20000704	US 1995-442581	19950516
	CA 2203936	AA	19960509	CA 1995-2203936	19951027
	WO 9613266	A1	19960509	WO 1995-US14117	19951027
	W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9641398	A1	19960523	AU 1996-41398	19951027
	AU 710564	B2	19990923		
	ZA 9509119	A	19960527	ZA 1995-9119	19951027
	EP 788360	A1	19970813	EP 1995-939670	19951027
	EP 788360	B1	20030528		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1168633	A	19971224	CN 1995-196590	19951027
	US 5780454	A	19980714	US 1995-549318	19951027
	JP 10510245	T2	19981006	JP 1996-514834	19951027
	NZ 337211	A	20001222	NZ 1995-337211	19951027
	IL 115790	A1	20021201	IL 1995-115790	19951027
	EP 1312609	A1	20030521	EP 2003-4280	19951027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 241631	E	20030615	AT 1995-939670	19951027
	PT 788360	T	20031031	PT 1995-939670	19951027
	ES 2199257	T3	20040216	ES 1995-939670	19951027
	IL 133831	A1	20040328	IL 1995-133831	19951027
	FI 9701746	A	19970606	FI 1997-1746	19970423
	NO 9701929	A	19970612	NO 1997-1929	19970425
	HK 1002059	A1	20030905	HK 1998-100951	19980207
	US 6066730	A	20000523	US 1998-85404	19980526
	US 6297217	B1	20011002	US 2000-490511	20000125
	US 6465433	B1	20021015	US 2001-953540	20010914
	US 2002173488	A1	20021121	US 2002-100295	20020318
	US 6548668	B2	20030415		
	US 6617317	B1	20030909	US 2002-125997	20020419
	US 2003199561	A1	20031023	US 2003-392165	20030319
	US 6747150	B2	20040608		
	US 2004167332	A1	20040826	US 2003-730231	20031208
PRAI	US 1994-330525	B2	19941028		
	US 1995-442581	A	19950516		
	EP 1995-939670	A3	19951027		
	IL 1995-115790	A3	19951027		
	NZ 1995-296717	A1	19951027		
	US 1995-549318	A3	19951027		
	WO 1995-US14117	W	19951027		
	US 1998-85404	A3	19980526		
	US 2000-490511	A1	20000125		
	US 2001-953540	A1	20010914		
	US 2002-100295	A1	20020318		
	US 2002-125997	A1	20020419		
	US 2003-392165	A1	20030319		

OS MARPAT 133:89798
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN
AN 1998:479021 CAPLUS
DN 129:122868

TI Preparation of peptidylboronic ester and acid compounds as **proteasome inhibitors**

IN **Adams, Julian**; Ma, Yu-Ting; Stein, Ross; Baevsky, Matthew; Grenier, Louis; Plamondon, Louis

PA Proscript, Inc., USA

SO U.S., 37 pp., Cont.-in-part of U.S. Ser. No. 442,581.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5780454	A	19980714	US 1995-549318	19951027
	US 6083903	A	20000704	US 1995-442581	19950516
	US 6066730	A	20000523	US 1998-85404	19980526
	US 6297217	B1	20011002	US 2000-490511	20000125
	US 6465433	B1	20021015	US 2001-953540	20010914
	US 2002173488	A1	20021121	US 2002-100295	20020318
	US 6548668	B2	20030415		
	US 6617317	B1	20030909	US 2002-125997	20020419
	US 2003199561	A1	20031023	US 2003-392165	20030319
	US 6747150	B2	20040608		
	US 2004167332	A1	20040826	US 2003-730231	20031208
PRAI	US 1994-330525	B2	19941028		
	US 1995-442581	A2	19950516		
	US 1995-549318	A3	19951027		
	US 1998-85404	A3	19980526		
	US 2000-490511	A1	20000125		
	US 2001-953540	A1	20010914		
	US 2002-100295	A1	20020318		
	US 2002-125997	A1	20020419		
	US 2003-392165	A1	20030319		

OS MARPAT 129:122868

RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT